Merck & Company Inc (MRK)vsRecursion Pharmaceuticals Inc (RXRX)
MRK
Merck & Company Inc
$143.81
-1.03%
HEALTHCARE · Cap: $365.34B
RXRX
Recursion Pharmaceuticals Inc
$4.07
-1.45%
HEALTHCARE · Cap: $2.05B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 121252% more annual revenue ($66.57B vs $54.86M). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
RXRX
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-74.5%
Fair Value
$83.26
Current Price
$143.81
$60.55 premium
Intrinsic value data unavailable for RXRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
0.0% margin — thin
ROE of -54.6% — below average capital efficiency
Revenue declined 60.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : RXRX
The strongest argument for RXRX centers on Debt/Equity, Price/Book.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : RXRX
The primary concerns for RXRX are EPS Growth, Profit Margin, Return on Equity.
Key Dynamics to Monitor
RXRX carries more volatility with a beta of 1.07 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (36/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Recursion Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?